Multiomic Health
ABOUT.
MultiOmic discovers and develops life-changing precision medicines for metabolic syndrome-derived diseases. Metabolic syndrome refers to a set of lifestyle and age-related risk factors — dysglycemia, hypertension, dyslipidemia, obesity — that lead to multiple (and often concurrent) serious medical conditions such as atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver. This group of closely-related conditions constitutes the world’s costliest healthcare burden, consuming $2 trillion in global healthcare costs in 2019 (1.6 times more than cancer), a cost that is forecast to exceed $5.5 trillion by 2040.
Using our unique combination of deep longitudinal patient datasets, AI-enabled data science capabilities and experimental biology expertise, we identify patient subpopulations having their own distinct molecular-level disease drivers. We use these insights to originate and pursue our own therapeutic R&D programmes, each with the corresponding patient-stratifying biomarkers. This precision medicine approach enables shorter and smaller clinical trials with inherently higher success rates.
MultiOmic commercialises its therapeutics programmes via licensing arrangements and partnerships with other biopharma companies. We also collaborate with diagnostic companies to implement our patient-stratifying biomarkers as companion diagnostics for our therapeutics.
TYPE 2
DIABETES
CHRONIC KIDNEY DISEASE
ATHEROSCLEROSIS
NON-ALCOHOLIC FATTY LIVER
OUR FOCUS.
In the near term, our work is focused on developing precision therapeutics for serious medical complications of diabetes including nephropathy, neuropathy, retinopathy and associated cardiovascular events.
We are investigating the underlying disease biology of these complications at the molecular level, using multiple omics modalities integrated with longitudinal clinical phenotyping.
The resulting insights will enable us to derive much more effective therapeutics and associated companion diagnostics optimised for specific patient subpopulations.
STATISTICS.
METABOLIC SYNDROME PANDEMIC
please view sidebar for data sources.
WHAT WE DO
MULTI Omic ANalysis.
GENOMICS
How someone's genes predispose disease and influence drug response
EPIGENOMICS
How ageing and external factors affect gene expression
PROTEOMICS
Which proteins are actually produced
METABOLOMICS
Which byproducts of metabolism are generated
UNDERSTANDING CHRONIC DISEASE BIOLOGY
EXPERTS IN THEIR FIELDS
OPERATING TEAM.
Robert Thong
Co-founder & CEO
30+ years in biopharma & healthcare, focusing on R&D management, B2B partnerships and value creation strategy. Has engaged with over 100 organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D partnerships and biotech business models
Ariella Cohain
CHIEF TECHNOLOGY OFFICER
Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion
Slaven Stekovic
CHIEF SCIENCE OFFICER
Forbes 30 under 30. Founded The Longevity Labs, whose nutraceutical is now marketed in >14 countries including USA, exited after 3 years. Leadership experience with two other startups in cancer genomics and AI-enabled robotics
Celia Antonio Schell
CHIEF OPERATING OFFICER
14 years experience in clinical research at Novartis and ICON. Recently managed a global Phase III clinical trial of >7,000 cardiovascular patients across 43 countries
Andrew Parton
Lead DATA SCIENTIST
Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research including journal papers on systems biology modeling of atherosclerosis
Valeryia Kuzmuk
LEAD DISEASE BIOLOGIST
Award-winning renal biologist. Has taken a novel therapeutic from unvalidated target to development candidate for Phase I. Previously at a UK biotech managing drug discovery assays and preclinical development studies
Esra Berkol
CHIEF OF STAFF & FINANCE MANAGER
Broad experience base of international collaborative activities. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Founded & exited own business
Karina Close
SENIOR BIOINFORMATICIAN
Experienced at analyzing and interpreting multi-omic patient and in vitro/in vivo data. Previously in the translational medicine data science team at Benevolent AI
Becky Cripps
BUSINESS DEVT. & ALLIANCE MGMT.
Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations
Henrietta Bull
PARTNERSHIPS & CORPORATE DEVT.
Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D
Heather Jackson
BIOINFORMATICIAN
Experienced at analyzing high-dimensional omics datasets and building bioinformatics pipelines. Previously a postdoc at Imperial College London
Laura Mitchell
SCIENCE & BUSINESS ANALYST
Previously interned at Immunocore, AstraZeneca and the Wellcome Sanger Institute
MULTIOMIC HEALTH IS A MEMBER OF
Contact.
Want to be a part of our team?
Got a partnership in mind?
Get in touch with us and know more about how we are changing the face of healthcare.
Multiomic Health Limited is a registered UK company
Company #13246608
Epworth House
25 City Road, Shoreditch, London, EC1Y 1AA
info@multiomic.health